Bull Hedging
  • Politics
  • Stocks
  • Business
  • Investing
  • Politics
  • Stocks
  • Business
  • Investing

Bull Hedging

Politics

Senate committee advances nomination of Dr Oz to run Centers for Medicare and Medicaid Services

by admin March 26, 2025
March 26, 2025
Senate committee advances nomination of Dr Oz to run Centers for Medicare and Medicaid Services

The Senate Committee on Finance voted along party lines Tuesday afternoon to advance Dr. Mehmet Oz, President Donald Trump’s pick to lead the Centers for Medicare and Medicaid Services, to a full confirmation vote. 

The party-line vote, which saw 14 GOP senators vote in favor of Oz’s nomination and 13 Democrats vote against it, follows two hearings by the Senate Finance Committee that probed Oz over his plans for the federal healthcare programs, his views on abortion, potential conflicts of interest in the healthcare industry and more.

‘Dr. Oz has years of experience as an acclaimed physician and public health advocate. His background makes him uniquely qualified for this role, and there is no doubt that he will work tirelessly to deliver much-needed change at CMS,’ Sen. Mike Crapo, R-Idaho, the chairman of the committee, said Tuesday. 

Oz graduated from Harvard University and received medical and business degrees from the University of Pennsylvania. He is a former heart surgeon who saw his fame rise through his appearances on daytime TV and 13 seasons of ‘The Dr Oz Show.’

Oz later transitioned into politics, launching an unsuccessful bid for Pennsylvania’s open Senate seat in 2022. He ultimately lost to John Fetterman, then the state’s lieutenant governor. 

If confirmed by the full Senate, Oz would be in charge of nearly $1.5 trillion in federal healthcare spending. Medicare, a federal healthcare program for seniors aged 65 and up, currently provides coverage for about 65 million Americans, according to the Center for Medicare Advocacy. Medicaid, which assists people with low incomes, covers roughly 72 million Americans, according to Medicaid.gov.

Oz’s leadership would direct decisions related to how the government covers procedures, hospital stays and medication within the federal healthcare programs, as well as the reimbursement rates at which healthcare providers get paid for their services.

Earlier this month, Trump’s pick to lead the NIH and FDA, Dr. Jay Bhattacharya and Dr. Marty Makary, respectively, were also approved in committee and are awaiting full confirmation votes in the Senate scheduled for later Tuesday. It is unclear when Oz’s full Senate vote will take place.

Around the same time that Bhattacharya and Makary won committee approval, Trump withdrew his nomination of former Florida Rep. David Weldon to run the CDC, over fears he did not have the GOP support to clear full confirmation. On Monday, the Trump administration named Susan Monarez, acting director of the CDC, as its new nominee.

This post appeared first on FOX NEWS

previous post
Trump FDA pick clears last hurdle after flipping vaccine question on Dem in confirmation hearing
next post
Biden-era guidance encouraged use of Signal app by highly-targeted govt officials: ‘Best practice’

Related Posts

Trump administration to shutter HHS’ long COVID office:...

March 26, 2025

Physician governor urges Capitol Hill to block RFK...

January 8, 2025

Federal courts will not make criminal referrals to...

January 4, 2025

The Hitchhiker’s Guide to confirming Trump Cabinet nominees...

January 15, 2025

GOP senator reveals strategy to push Trump’s policies...

March 7, 2025

Trump promises to ramp up energy production, lower...

March 5, 2025

Trump says US not willing to make deal...

April 7, 2025

Trump fires 17 government watchdogs at various federal...

January 26, 2025

2028 Watch: Here are the Democrats who may...

December 30, 2024

South Korea presidential ouster part of Chinese strategy...

April 5, 2025

Recent Posts

  • Unlock the Power of StockCharts’ NEW Market Summary Dashboard | Walkthrough & Tips
  • Market Maker Manipulation; Oops, They Did It Again!
  • 50% of S&P 500 Stocks Just Turned Bullish – What Happens Next?
  • Bullish Breadth Improvement Suggests Further Upside For Stocks
  • Tariff Tensions Ease, Nasdaq Soars — But is SMH the Emerging Leader?

Recent Comments

No comments to show.

About Us

About Us

Design Magazine

Welcome to Design Magazine. Follow us for daily & updated design tips, guide and knowledge.

Stay Connect

Facebook Twitter Instagram Pinterest Youtube Email

Recent Posts

  • Unlock the Power of StockCharts’ NEW Market Summary Dashboard | Walkthrough & Tips

    May 14, 2025
  • Market Maker Manipulation; Oops, They Did It Again!

    May 14, 2025
  • 50% of S&P 500 Stocks Just Turned Bullish – What Happens Next?

    May 14, 2025
  • Bullish Breadth Improvement Suggests Further Upside For Stocks

    May 14, 2025
  • Tariff Tensions Ease, Nasdaq Soars — But is SMH the Emerging Leader?

    May 14, 2025
  • Trump’s ‘wrong-headed’ effort to lower drug costs amounts to price control: expert

    May 14, 2025

Editors’ Picks

  • 1

    Small Caps are Set to Skyrocket in 2025—Here’s What You Need to Know

    December 12, 2024
  • 2

    Trump leaves China guessing what his next move is with unusual inauguration invitation

    December 15, 2024
  • 3

    Uranium Price Forecast: Top Trends That Will Affect Uranium in 2025

    December 19, 2024
  • 4

    Ad revenue should stabilize for media companies in 2025 — if they have sports

    December 31, 2024
  • 5

    Zinc Stocks: 4 Biggest Canadian Companies in 2025

    January 15, 2025
  • 6

    Trudeau declares himself ‘proud feminist’ after lamenting Harris loss to Trump as setback for women

    December 13, 2024
  • 7

    Lead Price Forecast: Top Trends for Lead in 2025

    January 11, 2025
Promotion Image

banner

Categories

  • Business (347)
  • Investing (1,114)
  • Politics (1,386)
  • Stocks (439)
  • About us
  • Contacts
  • Privacy Policy
  • Terms and Conditions
  • Email Whitelisting

Disclaimer: bullhedging.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.


Copyright © 2025 bullhedging.com | All Rights Reserved